Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pediatric Opioid Development Faces Grim Outlook After Advisory Cmte.

Executive Summary

Panelists appeared to have more questions than answers as the common cliché of 'more research is needed' dominated the two-day meeting.

Advertisement

Related Content

OxyContin Repeat? US FDA Seeks To Avoid Fallout Over Butrans Pediatric Data
Purdue's Butrans: US FDA Panel To Consider Pediatric Labeling, But Not A New Indication
Opana ER Panel Urged To Disregard ‘Invalid’ Human Abuse Liability Study
Opioid Development Strategies In Pediatrics To Get FDA Advisory Panel Help

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS119157

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel